Sobi® today announced the European Commission has granted Marketing Authorization for ALTUVOCT™ (efanesoctocog alfa), for the treatment and prevention of bleeds and perioperative prophylaxis in hemophilia A. ALTUVOCT is a high-sustained factor VIII replacement therapy for all ages and any disease severity.
WuXi debates sale of pharma operations as BIOSECURE Act advances – Pharmaceutical Technology
Sources from WuXi Biologics and WuXi Apptec say the companies are considering selling some of their operations as the Biosecure act moves through the US
October 6, 2024